|
Avdeeva V.A., Syachina S.N., Ejrih V.V., Zhmurov D.V., Zhmurov V.A.
Secondary hyperparathyroidism in patients with chronic kidney disease in Tyumen region: five-year follow-up data
|
№1 / 2024
|
|
Volgina G.V.
Calcimimetics in the treatment of secondary hyperparathyroisis in dialysis patients: comparison of the efficacy and safety of cinacalcet and etelcalcetide
|
№1 / 2022
|
|
P.N. Kislyy, E.V. Parshina, A.B. Zulkarnaev, A.D. Tolkach, S.S. Mikhailova, R.A. Chernikov, Ya.V. Zarya
Risk factors for development of severe hypocalciemia after paratyreoidectomy for secondary hyperparathyroidisis in dialysis patients
|
№3 / 2021
|
|
E.V. Shutov, G.V. Kotlyarova, K.M. Lysenko, G.V. Ryabinskaya, S.V. Lashutin, I.A. Markelova, S.Yu. Rubleva
Efficacy and safety of etelcalcetide compared with cinacalcet in patients received hemodialysis with secondary hyperparathyroidism. Results from a prospective randomized trial
|
№2 / 2021
|
|
G.V. Volgina, N.A. Mikhailovа
Ethelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients: a review of clinical data and a place in therapy
|
№2 / 2020
|
|
E.G. Dorofeeva
Early stages of CKD: problems and prospects
|
№1 / 2019
|
|
O.N. Vetchinnikova, T.A. Britvin, S.Yu. Gulimova
Chronic kidney disease and hyperparathyroidism: primary and/or secondary? (a case report)
|
№1 / 2016
|
|
R.P. Gerasimchuk, K.Ju. Novokshonov, A.Ju. Zemchenkov
Prevalence, course and opportunities for correction of secondary hyperparathyroidism in dialysis patients
|
№5-6 / 2015
|
|
L.Yu. Milovanova (1), A.A. Plotnikova (1), Yu.S. Milovanov (1), I.A. Dobrosmyslov (1), V.A. Anashkin (2), E.I. Il'inih (3), T.A. Yagupova (4)
Early treatment with phosphate-binders and active metabolites of vitamin D in prevention of secondary hyperparathyreoidism in patients with chronic kidney disease on program hemodialysis
|
№6 / 2013
|
|
O.N. Vetchinnikova, N.M. Zakharova
Therapeutic tactics in persistent and recurrent secondary (renal) hyperparathyroidism
|
№1 / 2013
|
|
L.Yu. Milovanova, Yu.S. Milovanov, I.A. Dobrosmislov
Secondary hyperparathyreoidism in chronic kidney disease. Role of fibroblast growth factor-23 (FGF-23) and Klotho
|
№1 / 2013
|
|
A.A. Plotnikova, L.Yu. Milovanova, Yu.S. Milovanov
Paricalcitol – new opportunities in nephroprotection and treatment of secondary hyperparathyreosis
|
№4 / 2012
|
Русский
